Companies: 10,795·Total market cap: $144.5T
Opus Genetics, Inc.

Opus Genetics, Inc.

IRDNASDAQHealthcare● Active
$4.03
+$0.00(+0.00%)
Market Cap$328024022
P/E Ratio
52W High$5.81
52W Low$0.9

Opus Genetics, Inc. (IRD) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ird · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 7 Wall Street analysts in the past 3 months

SellBuy

Buy

7 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
7
Hold
0
Sell
0
Strong Sell
0
Total: 7 · Buy rate: 100.0%

12-Month Price Target

High

$10.00

Consensus

$8.67

+115.1% upside

Low

$7.00

Median: $9 · Last Close: $4.03

The Opus Genetics, Inc. (IRD) analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month IRD price target is $8.67, representing +115.1% upside from the current price of $4.03.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $9 (115.1%)

Consensus Target

$8.67

115.1% upside

High Target

$10

148.1%

Low Target

$7

73.7%

Current Price

$4.03

as of today

Based on analyst price targets, the IRD stock price prediction for the next 12 months ranges from $7 to $10. The consensus IRD price forecast of $8.67 implies 115.1% upside from the current price of $4.03.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$3.873.88%

1-day model range: $3.84–$3.91. Peak: $3.91 (-3.88%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$8+103.6%
2028$13+219.5%
2029$17+319.7%
2030$20+392.0%
2031+438.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)42.1Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · IRD · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$4.18SELL
MA 10$4.18SELL
MA 20$4.43SELL
MA 50$4.86SELL
MA 100$4.24SELL
MA 200$3.05BUY
Current $IRD · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.16SELL
EMA 10$4.23SELL
EMA 20$4.41SELL
EMA 50$4.55SELL
EMA 100$4.16SELL
EMA 200$3.38BUY
Current $IRD · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Citizens2026-05-13
Maintains
Market OutperformMarket Outperform
Chardan Capital2026-03-12
Maintains
BuyBuy
Wedbush2026-03-12
Maintains
OutperformOutperform
BTIG2026-03-02
Maintains
BuyBuy
BTIG2026-01-28
Maintains
BuyBuy
Chardan Capital2025-11-13
Maintains
BuyBuy
Chardan Capital2025-11-07
Maintains
BuyBuy
HC Wainwright & Co.2025-06-27
Maintains
BuyBuy
HC Wainwright & Co.2025-04-01
Maintains
BuyBuy
Jones Trading2025-04-01
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Opus Genetics, Inc. (IRD) stock. Of the recent 17 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover IRD.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

IRD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$15M

↓ 51.7% YoY

Revenue Next Year

$16M

↑ 3.9% YoY

EPS This Year

$-1.07

EPS Next Year

$-0.72

↓ 32.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IRD EPS of $-1.07 for the current fiscal year, based on estimates from 10 analysts. The IRD revenue forecast is $15M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IRD stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IRD price target is $8.67 (+115.1% upside), with an analyst consensus of Buy.

The IRD short-term stock prediction for tomorrow is $3.87 (-3.88%). The IRD stock price prediction for 2027 estimates an average of $8. The IRD stock prediction for 2030 projects a range of $18–$22.

Opus Genetics, Inc. trades on NASDAQ under the ticker IRD. The IRD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IRD forecast · 8 questions

According to 7 Wall Street analysts, the average 12-month IRD price target is $8.67, with a high forecast of $10.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +115.1% potential upside from the current price of $4.03.

IRD price targetWhat is IRD price targetIRD analyst price targetIRD 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.